Trial Profile
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs LY 2880070 (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastrointestinal stromal tumours; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Esperas Pharma
- 11 Jan 2023 Planned End Date changed from 1 Jun 2021 to 30 Sep 2025.
- 11 Jan 2023 Planned primary completion date changed from 1 Mar 2020 to 30 Sep 2025.
- 11 Jan 2023 Planned number of patients changed from 185 to 229.